EN
Press Releases
-
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months
-
BEIJING, April 30, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it filed
-
Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.
-
2026/03/30
SINOVAC and Bio Farma Sign Strategic MoU to Advance Cooperation and Support Global Public Health
BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20
-
![A Study Published in <i>Vaccines</i> Supports Co-administration of SINOVAC's sIPV with MMR and Hepatitis A Vaccines in Children]()
BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is
-
![SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing]()
BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (
-
![<i>Vaccines</i> Publishes Real-World Study Supporting Safety of SINOVAC's Varicella Vaccine in Children Aged 7–12]()
BEIJING, January 20, 2026 – A large-scale real-world study published in the peer-reviewed journal Vaccines showed that SINOVAC's live attenuated varicella vaccine (VarV) has a stable and favorable
-
![A Study Published in the <i>International Journal of Infectious Diseases</i> Supports Co-administration of SINOVAC's Varicella and Trivalent Influenza Vaccines in Children Aged 7–12]()
BEIJING, January 20, 2026 – Co-administration of SINOVAC’s live attenuated varicella vaccine (VarV) and trivalent inactivated influenza vaccine (Anflu®) was shown to be safe and immunogenic in in heal
-
![SINOVAC Secures Exclusive 2026 Influenza Vaccine Supply Contract in Chile]()
BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the
-
![Sinovac Initiates Volunteer Enrollment for its Phase I/II Clinical Study on Lyophilized Herpes Zoster mRNA Vaccine]()
BEIJING, Jan. 7, 2026 – On January 6, 2026, Sinovac Life Sciences Co., Ltd., a subsidiary of Sinovac Biotech Ltd. (“SINOVAC” or the “Company”), initiated the enrollment of volunteer subjects for a Pha
-
![SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement]()
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Co
-
![Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting]()
BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the dire